Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The alpha-1 beta-2 delta (alpha1beta2delta) GABA-A receptor is a specialized subtype of the ionotropic gamma-aminobutyric acid receptor, predominantly located extrasynaptically on parvalbumin-positive (PV+) interneurons (Farrant & Nusser, 2005, Nature Reviews Neuroscience). Unlike synaptic receptors containing the gamma subunit that mediate fast phasic inhibition, this delta-containing assembly is highly sensitive to low concentrations of ambient GABA and mediates a continuous tonic inhibitory current (Mody & Pearce, 2004, Annual Review of Neuroscience). This tonic inhibition is essential for controlling the gain and temporal precision of PV+ interneuron firing, which in turn orchestrates gamma-frequency oscillations necessary for cognitive processes like attention and memory (Mann & Mody, 2010, Nature Reviews Neuroscience). Dysfunctional alpha1beta2delta signaling is linked to the pathophysiology of epilepsy and schizophrenia, where impaired PV+ cell activity disrupts neural network synchronization (Lewis et al., 2012, Nature Reviews Neuroscience). Pharmacologically, these receptors are highly sensitive to neurosteroids like brexanolone and ganaxolone, as well as the selective agonist gaboxadol, offering a pathway for targeted modulation of inhibitory tone (Belelli & Lambert, 2005, Nature Reviews Neuroscience). Targeting this specific receptor population provides a mechanism to treat neurohyperexcitability and mood disorders with potentially fewer side effects than non-selective benzodiazepines.
Positive allosteric modulation and direct agonism of the GABA-A receptor complex to increase chloride conductance and mediate tonic inhibition.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-aminobutyric acid type A receptor alpha-1 beta-2 delta (alpha1beta2delta GABAA receptor) (alpha1beta2delta GABAA receptor).